ASX:MSB

	Last	Movement		Open	High	Low	Volume
ASX:MSB	$2.920	-$0.013	-0.45%	$2.960	$2.960	$2.840	141,702

Data Source:

Last Updated: 23/01/2020 10:28 AM

Email Alerts for:
ASX:MSB

Why the Aussie share market has more upside

20 Jan 2020 - Fairmont Equities Managing Director Michael Gable takes a technical look at why the Aussie share market has more upside

Mesoblast (ASX:MSB) presents at Biotech showcase in San Francisco

15 Jan 2020 - Mesoblast (ASX:MSB) presents at Biotech showcase in San Francisco.

Mesoblast (ASX:MSB) files positive clinical efficacy and safety data

02 Jan 2020 - Cellular medicinal provider, Mesoblast (ASX:MSB, NASDAQ:MESO) has lodged positive clinical efficacy and safety data with the US FDA for its lead product candidate, re…

Global stocks fall on economic growth worries: ASX closes 2.2% lower

03 Oct 2019 - It has been a disappointing day of trade for the ASX. After opening in the black the local bourse failed to gain momentum to close 2.2% lower. Ooh!Media (ASX:OML) dro…

Mesoblast completes $75 million capital raising

03 Oct 2019 - Leader in cellular medicines for inflammatory diseases, Mesoblast (ASX:MSB) has successfully completed a $75 million capital raising.

Mesoblast see strong commercialisation revenues for the quarter

30 Jul 2019 - Mesoblast (ASX:MSB) today reported its operational highlights for their fourth quarter showing growth in revenues achieved by their Japanese partner in the treatment …

Property prices fall more than expected: Aus shares bounce back, 0.4% higher at noon

18 Jun 2019 - The local share market bounces back from yesterday’s fall, rising 0.4% at noon with most sectors charging higher. Property prices fall 3% in March Qtr, more than 2.5%…

Mesoblast expands JCR partnership to brain disease in newborns

11 Jun 2019 - Mesoblast (ASX:MSB) has today announced it has expanded its partnership with JCR Pharmaceuticals in Japan (to the use of mesenchymal stem cells (MSCs)) for the treatm…

Mesoblast enters MoU for US clinical trial for Revascor

27 Mar 2019 - Mesoblast (ASX:MSB) today announced that the International Center for Health Outcomes and Innovation Research have entered into a MoU for a clinical trial using Mesob…

Mesoblast draws down $15m of capital to accelerate product commercialisation programs

14 Jan 2019 - Mesoblast (ASX:MSB) has today announced it has drawn down (a further) $15 million from its US$75 million four-year credit facility with Hercules Capital.

Healius shares dip after rejecting takeover offer: ASX is 1.5% higher at noon

07 Jan 2019 - The ASX has continued to rise throughout this morning after the US posted solid gains on Friday after a boost from impressive employment data from all jobs except far…

Christmas holiday week ends on the up: ASX closes 1.02% higher

28 Dec 2018 - It has been a positive day of trade for the Australian share market as the market closed in positive territory. Most of this week's gains came on Thursday. The big fo…

Mesoblast pipeline growth in regenerative medicine industry

28 Dec 2018 - Mesoblast (ASX:MSB) today released their corporate review showing how the company will enter 2019 with the most mature cell therapy product pipeline and technology pl…

Santa sleigh leads ASX lower: Aus shares 0.2% lower at noon

19 Dec 2018 - Mid-session report. ASX continues to slide on oil slipping further amid less oil demand. Inghams Group's (ASX:ING) Joel Thickins to retire, its shares trade 26% highe…

US stocks rise on trade hopes: ASX poised to open higher

16 Nov 2018 - The ASX is set to open higher amid optimism that China and the US are seeking to resolve their trade spat. Wall St had a rollercoaster of a day. US stocks rose for th…

Mesoblast join with Tasly for China deal

12 Oct 2018 - Regenerative medicine comapny Mesoblast (ASX:MSB) today announced completion of the transaction with Tasly Pharmaceutical Group to establish a strategic partnership i…

Rates to hold for 25th time: ASX slips 0.5% at noon, back to June levels

02 Oct 2018 - Market at Midday. ASX200 wipes out 3 months of gains and takes the market back to June levels. Rates to hold for 25th time. Most sectors lower. Mesoblast down 9.4% de…

Mesoblast (ASX:MSB) Presentation, FNN Investor Event, August 2018, Sydney

22 Aug 2018 - Mesoblast Limited (ASX:MSB) Head of Business Development and Licensing, David Oxley, presents details about the company's Phase 3 trials, its agreement with Tasly Chi…

Mesoblast (ASX:MSB) talks disruptive cellular medicines

22 Aug 2018 - Mesoblast Limited (ASX:MSB) Head, Business Development and Licensing, David Oxley, discusses the company's Phase 3 trials, its agreement with Tasly China and the near…

ANZ shares have further to run

23 Jul 2018 - Fairmont Equities managing director Michael Gable takes a technical look at Australia and New Zealand Banking Group (ASX:ANZ), the ASX200, Doray Minerals (ASX:DRM), T…

Nasdaq hits record high: Aus shares set to rise

18 Jul 2018 - Australian shares are set to lift at the open, bolstered by gains on Wall Street overnight. Mesoblast (ASX:MSB) has inked a deal with Tasly Pharmaceutical Group.

Mesoblast appoints Shawn Cline Tomasello to Board

11 Jul 2018 - Cellular medicine company, Mesoblast (ASX:MSB) has announced that Shawn Cline Tomasello has joined its Board of Directors.

China tariff stress: Aus shares 0.3% higher at noon

19 Jun 2018 - The Australian share market has seen its strong advance falter after President Trump’s threat of new tariffs on China. It is still sitting above yesterday's close des…

Mesoblast bigger revenues, loss drops and hires new CFO

31 May 2018 - Mesoblast (ASX:MSB) reports after tax loss of US$14.5 million in the nine months to 31 March 2018, an improvement of 71 per cent. It also bumps up revenue and R&D spe…

Lithium shines again: Aus shares close 0.16% higher

29 May 2018 - Market Wrap. ASX claws back some of yesterdays loses. Lithium players charged ahead today with Galaxy Resources (ASX:GXY) and Orocobre (ASX:ORE) taking the first and …